Yayın:
Prognostic value of choroidal vascular index in determining response to intravitreal dexamethasone implant treatment used in refractory diabetic macular edema

dc.contributor.authorİlgüy, Serdar
dc.contributor.authorIşık, Mehmed Uğur
dc.date.accessioned2026-01-04T18:20:53Z
dc.date.issued2023-01-21
dc.description.abstractTo investigate the effect of intravitreal dexamethasone (IVD) implant injection, which was used in the treatment of DME, on CVI and to investigate whether CVI can be used as a prognostic marker in the treatment of anti-VEGF resistant DME. A retrospective observational and comparative study. Twenty-five eyes of 25 patients with refractory diabetic macular edema who underwent intravitreal dexamethasone (IVD) implant and 50 eyes of 50 healthy patients were included in the study. Central macular thickness (CMT), subfoveal choroidal thickness (SFCT), luminal choroidal area (LCA), total choroidal area (TCA), stromal choroidal area (SCA), and choroidal vascularity index (CVI) were measured on optical coherence tomography. There was no significant difference between the groups in terms of age and gender. When the pre-treatment values in the IVD group were compared with the healthy group, LCA and SCA values were higher, and CVI ratios were lower in the IVD group compared to the control group. When baseline, 1st, and 3rd months after injection were compared, it was determined that there was a significant decrease in CMT and LCA. There was no statistically significant difference in SFCT, TCA, and CVI. There was a significant negative correlation between baseline CVI and 3rd month CMT after IVD (rho: - 0.643, p: 0.001). It was observed that the baseline and 1st month LCA values were significantly higher than the 3rd month. The choroidal vascular structure may be affected by IVD treatment. CVI may also have value as a prognostic marker in monitoring the response to treatment.
dc.description.urihttps://doi.org/10.1007/s10103-023-03711-7
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/36680633
dc.identifier.doi10.1007/s10103-023-03711-7
dc.identifier.eissn1435-604X
dc.identifier.openairedoi_dedup___::a21d04251cbe9639a8ba0f3e0fdb99ef
dc.identifier.orcid0000-0002-5003-3834
dc.identifier.pubmed36680633
dc.identifier.scopus2-s2.0-85147331888
dc.identifier.urihttps://hdl.handle.net/20.500.12597/40471
dc.identifier.volume38
dc.identifier.wos000919033900001
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofLasers in Medical Science
dc.rightsCLOSED
dc.subjectDiabetic Retinopathy
dc.subjectChoroid
dc.subjectDiabetes Mellitus
dc.subjectHumans
dc.subjectPrognosis
dc.subjectMacular Edema
dc.subjectDexamethasone
dc.subjectTomography, Optical Coherence
dc.subjectRetrospective Studies
dc.subject.sdg3. Good health
dc.titlePrognostic value of choroidal vascular index in determining response to intravitreal dexamethasone implant treatment used in refractory diabetic macular edema
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Serdar İlgüy","name":"Serdar","surname":"İlgüy","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0002-5003-3834"},"provenance":null}},{"fullName":"Mehmed Uğur Işık","name":"Mehmed Uğur","surname":"Işık","rank":2,"pid":null}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Diabetic Retinopathy"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Choroid"},"provenance":null},{"subject":{"scheme":"keyword","value":"Diabetes Mellitus"},"provenance":null},{"subject":{"scheme":"keyword","value":"Humans"},"provenance":null},{"subject":{"scheme":"keyword","value":"Prognosis"},"provenance":null},{"subject":{"scheme":"keyword","value":"Macular Edema"},"provenance":null},{"subject":{"scheme":"keyword","value":"Dexamethasone"},"provenance":null},{"subject":{"scheme":"keyword","value":"Tomography, Optical Coherence"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"keyword","value":"Retrospective Studies"},"provenance":null}],"mainTitle":"Prognostic value of choroidal vascular index in determining response to intravitreal dexamethasone implant treatment used in refractory diabetic macular edema","subTitle":null,"descriptions":["To investigate the effect of intravitreal dexamethasone (IVD) implant injection, which was used in the treatment of DME, on CVI and to investigate whether CVI can be used as a prognostic marker in the treatment of anti-VEGF resistant DME. A retrospective observational and comparative study. Twenty-five eyes of 25 patients with refractory diabetic macular edema who underwent intravitreal dexamethasone (IVD) implant and 50 eyes of 50 healthy patients were included in the study. Central macular thickness (CMT), subfoveal choroidal thickness (SFCT), luminal choroidal area (LCA), total choroidal area (TCA), stromal choroidal area (SCA), and choroidal vascularity index (CVI) were measured on optical coherence tomography. There was no significant difference between the groups in terms of age and gender. When the pre-treatment values in the IVD group were compared with the healthy group, LCA and SCA values were higher, and CVI ratios were lower in the IVD group compared to the control group. When baseline, 1st, and 3rd months after injection were compared, it was determined that there was a significant decrease in CMT and LCA. There was no statistically significant difference in SFCT, TCA, and CVI. There was a significant negative correlation between baseline CVI and 3rd month CMT after IVD (rho: - 0.643, p: 0.001). It was observed that the baseline and 1st month LCA values were significantly higher than the 3rd month. The choroidal vascular structure may be affected by IVD treatment. CVI may also have value as a prognostic marker in monitoring the response to treatment."],"publicationDate":"2023-01-21","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_14cb","label":"CLOSED","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Lasers in Medical Science","issnPrinted":null,"issnOnline":"1435-604X","issnLinking":null,"ep":null,"iss":null,"sp":null,"vol":"38","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::a21d04251cbe9639a8ba0f3e0fdb99ef","originalIds":["3711","10.1007/s10103-023-03711-7","50|doiboost____|a21d04251cbe9639a8ba0f3e0fdb99ef","36680633"],"pids":[{"scheme":"doi","value":"10.1007/s10103-023-03711-7"},{"scheme":"pmid","value":"36680633"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":1,"influence":2.56661e-9,"popularity":2.9073586e-9,"impulse":1,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1007/s10103-023-03711-7"}],"license":"Springer Nature TDM","type":"Article","urls":["https://doi.org/10.1007/s10103-023-03711-7"],"publicationDate":"2023-01-21","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"36680633"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s10103-023-03711-7"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/36680633"],"publicationDate":"2023-01-24","refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar